Ana Vanessa Nascimento1,2,3, Florence Gattacceca4, Amit Singh3, Hassan Bousbaa1,5, Domingos Ferreira2, Bruno Sarmento1,6, Mansoor M Amiji3,7. 1. CESPU, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde, Gandra, Portugal. 2. Laboratory of Pharmaceutical Technology, Faculty of Pharmacy, University of Porto, Portugal. 3. Department of Pharmaceutical Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, MA, USA. 4. Institut de Recherche en Cancérologie de Montpellier IRCM, INSERM U1194, ICM, Université de Montpellier, Montpellier, France. 5. Centro Interdisciplinar de Investigação Marinha e Ambiental (CIIMAR/CIMAR), Universidade do Porto, Portugal. 6. I3S, Instituto de Investigação e Inovação em Saúde and INEB - Instituto de Engenharia Biomédica, Universidade do Porto, Portugal. 7. Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
Abstract
BACKGROUND: The present study focuses on biodistribution profile and pharmacokinetic parameters of EGFR-targeted chitosan nanoparticles (TG CS nanoparticles) for siRNA/cisplatin combination therapy of lung cancer. MATERIAL & METHODS: Mad2 siRNA was encapsulated in EGFR targeted and nontargeted (NTG) CS nanoparticles by electrostatic interaction. The biodistribution of the nanoparticles was assessed qualitatively and quantitatively in cisplatin (DDP) sensitive and resistant lung cancer xenograft model. RESULTS: TG nanoparticles showed a consistent and preferential tumor targeting ability with rapid clearance from the plasma to infiltrate and sustain within the tumor up to 96 h. They exhibit a sixfold higher tumor targeting efficiency compared with the NTG nanoparticles. CONCLUSION: TG nanoparticles present as an attractive drug delivery platform for RNAi therapeutics against NSCLC.
BACKGROUND: The present study focuses on biodistribution profile and pharmacokinetic parameters of EGFR-targeted chitosan nanoparticles (TG CS nanoparticles) for siRNA/cisplatin combination therapy of lung cancer. MATERIAL & METHODS:Mad2 siRNA was encapsulated in EGFR targeted and nontargeted (NTG) CS nanoparticles by electrostatic interaction. The biodistribution of the nanoparticles was assessed qualitatively and quantitatively in cisplatin (DDP) sensitive and resistant lung cancer xenograft model. RESULTS: TG nanoparticles showed a consistent and preferential tumor targeting ability with rapid clearance from the plasma to infiltrate and sustain within the tumor up to 96 h. They exhibit a sixfold higher tumor targeting efficiency compared with the NTG nanoparticles. CONCLUSION: TG nanoparticles present as an attractive drug delivery platform for RNAi therapeutics against NSCLC.
Authors: K M Monirul Islam; Xiaqing Jiang; Trisari Anggondowati; Ge Lin; Apar Kishor Ganti Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-06-11 Impact factor: 4.254
Authors: Srinivas Ganta; Amit Singh; Praveen Kulkarni; Amanda W Keeler; Aleksandr Piroyan; Rupa R Sawant; Niravkumar R Patel; Barbara Davis; Craig Ferris; Sara O'Neal; William Zamboni; Mansoor M Amiji; Timothy P Coleman Journal: Pharm Res Date: 2015-03-04 Impact factor: 4.200
Authors: Min Ju Kim; Jong-Sung Park; So Jin Lee; Jiyeon Jang; Jin Su Park; Seung Hyun Back; Gahee Bahn; Jae Hyung Park; Young Mo Kang; Sun Hwa Kim; Ick Chan Kwon; Dong-Gyu Jo; Kwangmeyung Kim Journal: J Control Release Date: 2015-08-14 Impact factor: 9.776